Myxoid liposarcoma Treatment

Surgery as the Primary Treatment

Surgery remains the cornerstone of treatment for myxoid liposarcoma. The surgeon's goal is to remove the entire tumor along with a border of normal tissue surrounding it. This border, called a surgical margin, is crucial because it helps ensure that any cancer cells that have spread microscopically beyond the visible tumor are also removed.1

The surgical approach varies depending on where the tumor is located and how large it has become. For tumors in the arms or legs, surgeons work carefully to preserve as much function as possible while ensuring complete removal of the cancer. They aim to avoid damaging important structures like nerves, blood vessels, and muscles that are essential for movement and sensation. This delicate balance between removing all cancer cells and preserving limb function requires significant surgical expertise.3

In rare situations where the tumor has grown extensively and involves critical structures that cannot be preserved, amputation may be considered. However, modern surgical techniques and the addition of radiation therapy have made limb-sparing surgery possible for most patients. The surgical team evaluates each case individually to determine the best approach that maximizes both cancer removal and quality of life.3

After surgery, the removed tissue is examined under a microscope by a pathologist—a doctor who specializes in diagnosing disease by studying cells and tissues. The pathologist checks whether the surgical margins are clear, meaning no cancer cells are found at the edges of the removed tissue. If cancer cells are present at the margins, additional treatment may be needed to reduce the risk of the tumor returning.1

Radiation Therapy

Radiation therapy uses high-energy beams to destroy cancer cells or prevent them from growing. For myxoid liposarcoma, radiation therapy serves several important purposes and can be given at different times relative to surgery.2

Preoperative radiation, also called neoadjuvant radiation, is given before surgery to shrink the tumor. Making the tumor smaller can make it easier for the surgeon to remove it completely and may help preserve more healthy tissue and function. This approach is particularly useful when the tumor is large or located near important structures that need to be protected.1

Postoperative radiation, also called adjuvant radiation, is given after surgery to destroy any remaining cancer cells that might be too small to see. This approach is often used when the surgical margins are close or when there is concern that microscopic disease might remain. It helps reduce the chance of the tumor coming back in the same location, which is called local recurrence.2

Research has shown that myxoid liposarcoma responds particularly well to radiation therapy compared to other types of liposarcoma. This makes radiation an especially valuable tool in the treatment of this specific cancer subtype. The radiation oncologist carefully plans the treatment to deliver the maximum dose to the tumor area while minimizing exposure to surrounding healthy tissues.3

The typical course of radiation therapy involves daily treatments over several weeks. Each treatment session is short, usually lasting only a few minutes, though the entire appointment may take longer due to positioning and preparation. Common side effects include fatigue, skin changes in the treated area similar to sunburn, and temporary swelling. Most side effects gradually improve after treatment ends.4

Chemotherapy

Chemotherapy uses drugs to kill cancer cells throughout the body. For myxoid liposarcoma, chemotherapy may be used in several situations. It is most commonly considered when the tumor cannot be completely removed by surgery, when the tumor has spread to other parts of the body, or when the tumor contains a high percentage of aggressive round cells.1

Studies have found that myxoid liposarcoma is more sensitive to chemotherapy than other liposarcoma subtypes. This means that chemotherapy drugs are more likely to have an effect on the tumor cells and may help control the disease. However, the decision to use chemotherapy depends on many factors, including the stage of the disease, the patient's overall health, and whether the tumor has certain aggressive features.4

Two specific drugs have been approved by the U.S. Food and Drug Administration for liposarcoma that cannot be removed by surgery or has spread to other parts of the body. Trabectedin is an alkylating drug that works by binding to DNA inside cancer cells, preventing them from dividing and growing. It was approved in 2015 for patients who have already received treatment with anthracycline-containing chemotherapy regimens.4

Eribulin is another approved drug that works differently—it is a microtubule inhibitor that interferes with the cell's ability to divide. This drug was approved in 2016 specifically for liposarcoma that cannot be removed or has spread, again for patients who have already tried anthracycline-based chemotherapy. In studies focusing on liposarcoma patients, eribulin showed an improvement in survival time compared to another chemotherapy drug called dacarbazine.4

Chemotherapy can cause various side effects depending on the specific drugs used. Common side effects include fatigue, nausea, hair loss, increased risk of infections due to lowered blood cell counts, and numbness or tingling in the hands and feet. The medical team monitors patients closely during chemotherapy and provides supportive care to manage these side effects.4

Understanding Clinical Trial Phases

Clinical trials are research studies that test new treatments to see if they are safe and effective. These trials happen in several phases, each with a specific purpose. Phase I trials focus mainly on safety, testing a new treatment in a small group of people to determine the correct dose and identify side effects. Phase II trials expand to a larger group to evaluate whether the treatment actually works against the disease and to further assess safety. Phase III trials compare the new treatment to the current standard treatment in an even larger group of patients to determine which approach is better.5

Targeted Molecular Therapies

Scientists have discovered that myxoid liposarcoma has specific genetic characteristics that make it different from other cancers. In almost all cases, a genetic change occurs where two genes that are normally on different chromosomes join together abnormally. Most commonly, a gene called FUS fuses with a gene called CHOP, creating what is called a fusion gene. This fusion happens in about 90% of myxoid liposarcoma cases. In the remaining 10%, a different gene called EWSR1 fuses with CHOP instead.6

Understanding these genetic changes has opened the door to developing targeted therapies—treatments designed to specifically attack cancer cells with these genetic abnormalities while leaving normal cells relatively unharmed. Researchers are working to create drugs that can interfere with the proteins produced by these fusion genes, potentially stopping the cancer cells from growing and dividing.6

Another important genetic finding in some liposarcomas involves the MDM2 and CDK4 genes. Some myxoid liposarcomas show amplification of these genes, meaning the cells have extra copies. MDM2 interferes with a protein called p53 that normally helps prevent cancer, while CDK4 pushes cells to divide more rapidly. Drugs that target these pathways are being studied to see if they can help control tumor growth in patients whose tumors have these genetic changes.4

Improved Chemotherapy Approaches

While standard chemotherapy drugs like trabectedin and eribulin have already been approved, researchers continue to test new combinations and schedules of these and other drugs. Clinical trials are exploring whether giving chemotherapy before surgery might help shrink tumors more effectively, whether certain drug combinations work better than single drugs, and whether chemotherapy given in specific patterns can reduce side effects while maintaining effectiveness.5

Some clinical trials are specifically studying whether myxoid liposarcoma responds differently to treatment based on the percentage of round cells present in the tumor. Tumors with higher percentages of round cells tend to be more aggressive and may benefit from more intensive chemotherapy approaches. Understanding these differences helps researchers design better treatment strategies tailored to tumor characteristics.7

Clinical Trial Locations and Eligibility

Clinical trials for myxoid liposarcoma are conducted at specialized cancer centers and academic medical institutions around the world, including locations in the United States, Europe, and other regions. Major cancer centers often have dedicated sarcoma programs that coordinate multiple trials specifically for rare cancers like myxoid liposarcoma.5

To participate in a clinical trial, patients typically need to meet specific criteria called eligibility requirements. These may include factors such as the stage of disease, previous treatments received, overall health status, and specific characteristics of the tumor. Some trials are specifically designed for patients whose disease has spread or returned after initial treatment, while others may accept patients who are newly diagnosed.5

Patients interested in clinical trials should discuss this option with their oncology team. Specialized cancer centers and organizations dedicated to rare cancers often maintain databases of available clinical trials that patients and doctors can search to find appropriate studies. Participation in clinical trials not only provides access to potentially beneficial new treatments but also contributes to advancing knowledge that will help future patients with the same condition.3